UPDATE : Monday, October 21, 2019
상단여백
Pharmicell submits investigational new drug application for prostate cancer treatment by Lee Han-soo 2019-08-05 17:59
Sillajen’s trouble heralds fall of one of most prominent biotech firms by Lee Han-soo 2019-08-05 16:55
SillaJen remains confident about Pexa-Vec’s value, despite trial failure by Jeong Sae-im 2019-08-05 14:49
Suspicions resurge over SillaJen execs’ stock selling before Pexa-Vec trial suspension by Jeong Sae-im 2019-08-05 11:26
Biotech shares tank amid SillaJen’s likely halt of Pexa-Vec trial by Jeong Sae-im 2019-08-02 15:45
라인
Eutilex pipelines are underrated: CEO by Jeong Sae-im 2019-08-01 16:08
Samsung BioLogics records Q2 operating loss by Lee Han-soo 2019-07-25 10:16
Samsung Bioepis biosimilar sales in EU top $180 million in Q1 by Lee Han-soo 2019-07-24 15:29
Celltrion Healthcare joins Australia's pharma industry group by Lee Han-soo 2019-07-22 15:13
Samsung BioLogics’ fate remains uncertain amid litigating ups and downs by Lee Han-soo 2019-07-19 18:16
라인
EU starts evaluating Samsung Bioepis’ sales application for Avastin biosimilar by Lee Han-soo 2019-07-19 17:01
Celltrion targets Chinese biosimilar market through joint venture by Lee Han-soo 2019-07-19 14:53
Biopharmaceutical stocks face grim outlook in 2H by Jeong Sae-im 2019-07-17 14:11
Celltrion starts P1 trial of Xolair biosimilar by Lee Han-soo 2019-07-15 17:45
Doctors question Pexa-Vec+Imfinzi combo’s effect on colon cancer by Jeong Sae-im, Kim Yun-mi 2019-07-12 15:13
라인
Court suspends decision on ministry’s order to revoke Invossa license by Jeong Sae-im 2019-07-12 13:11
Prosecutors raid 2 lead managers of Kolon TissueGene’s IPO by Jeong Sae-im 2019-07-11 16:39
NKMax America seeks NASDAQ listing by Jeong Sae-im 2019-07-11 12:41
Psomagen seeks KOSDAQ listing using technology exception policy by Jeong Sae-im 2019-07-10 15:20
Kolon files administrative suit against Invossa license revocation by Jeong Sae-im 2019-07-09 11:47
여백
여백
여백
Back to Top